Mixtard 30 Innolet (Insulin Human)

Insulin Human binds to insulin receptors on muscle, fat and liver cells, activating intracellular signaling that promotes glucose uptake via GLUT4 transporters and suppresses hepatic glucose production. The combined short‑acting and intermediate‑acting components in Mixtard 30 Innolet deliver rapid post‑prandial control together with longer‑lasting basal insulin effects.

The dose of Mixtard 30 Innolet is individualized. A qualified prescriber determines the total daily insulin requirement based on the patient’s blood glucose readings, diet, activity level and other medications. The dose may be adjusted over time to maintain optimal glycemic control while minimizing the risk of hypoglycemia.

Safety data for Insulin Human in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. It should be used during pregnancy or while breastfeeding only if the potential benefits justify any potential risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Mixtard 30 Innolet product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Mixtard 30 Innolet is a premixed insulin containing a fixed ratio of short‑acting and intermediate‑acting insulin human, offering convenience compared with separate basal and bolus injections. Compared with rapid‑acting analogues, it may have a slightly slower onset but provides a predictable basal component, making it suitable for patients who prefer fewer daily injections.

Store Mixtard 30 Innolet refrigerated at 2‑8 °C (36‑46 °F). Protect the vial from direct light and do not freeze. Before use, gently roll the vial to mix the suspension; do not shake vigorously. Once opened, the product may be kept at controlled room temperature (up to 25 °C) for a limited period as indicated on the label.

Mixtard 30 Innolet is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection should be given at a 90‑degree angle using a suitable needle, rotating sites with each dose to reduce the risk of lipodystrophy. Patients should be instructed on proper technique and disposal of sharps.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Insulin edema and cardiovascular events may also occur, particularly in patients with pre‑existing heart disease. Prompt medical attention is required if any of these serious reactions are suspected.

Mixtard 30 Innolet is contraindicated in individuals with a known hypersensitivity to insulin human, any of the excipients in the formulation, or a history of severe allergic reactions to insulin products. It should also be avoided in patients with hypoglycemia unawareness unless closely monitored by a healthcare professional.